ClinConnect ClinConnect Logo
Search / Trial NCT04378790

A Randomized Trial to Evaluate Sequential vs Simultaneous Patching

Launched by JAEB CENTER FOR HEALTH RESEARCH · May 5, 2020

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Patching Glasses Spectacles Simultaneous Sequential

ClinConnect Summary

This clinical trial is studying the best way to treat amblyopia, often known as "lazy eye," in children aged 3 to just under 13 years. Specifically, it will compare two treatment methods: one where children wear glasses first and only use a patch if needed later, and another where they wear glasses and a patch at the same time. The goal is to see if both approaches lead to similar improvements in vision.

To be part of this study, children need to have amblyopia linked to issues like differences in eye strength (anisometropia) or misaligned eyes (strabismus). They should not have received any prior treatment for amblyopia. Participants will wear glasses prescribed for their specific needs and may be asked to wear a patch over the stronger eye to help improve vision in the weaker one. Parents should know that the study is ongoing and that their child will be randomly assigned to one of the two treatment methods, with the aim of making vision better.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • 1. Age 3 to \<13 years at the time of randomization
  • 2. Amblyopia associated with anisometropia, strabismus, or both
  • o Criteria for strabismic amblyopia: At least one of the following must be met:
  • Presence of a heterotropia on examination at distance or near fixation (with or without optical correction)
  • Documented history of strabismus which is no longer present (which in the judgment of the investigator could have caused amblyopia)
  • * Criteria for anisometropia: At least one of the following criteria must be met:
  • 1.00 D difference between eyes in spherical equivalent (SE)
  • 1.50 D difference in astigmatism between corresponding meridians in the two eyes
  • * Criteria for combined-mechanism amblyopia: Both of the following criteria must be met:
  • Criteria for strabismus are met (see above)
  • 1.00 D difference between eyes in spherical equivalent OR ≥1.50 D difference in astigmatism between corresponding meridians in the two eyes
  • 3. No previous treatment for amblyopia, including no more than 24 hours of spectacle wear.
  • 4. Investigator planning to initiate spectacle correction of refractive error meeting the following criteria based on a cycloplegic refraction that has been performed within 30 days:
  • 1. Full correction of anisometropia
  • 2. Full correction of astigmatism with the same axis found by the cycloplegic refraction
  • 3. Full correction of any myopia
  • 4. Hyperopia must not be under corrected by more than 1.50 D, and reduction in plus sphere must be symmetric in the two eyes.
  • 5. At enrollment, single VA measured in each eye assessed in trial frames with the spectacle correction the investigator plans to prescribe, using the investigator's routine method as follows:
  • VA in the amblyopic eye 20/40 to 20/200 inclusive.
  • Age-normal VA in the fellow eye:40,41
  • 3 years: 0.4 logMAR (20/50) or better
  • 4 years: 0.3 logMAR (20/40) or better
  • 5-6 years: 0.2 logMAR (20/32) or better
  • 7-12 years: 0.12 logMAR (78 letters) or better
  • Interocular difference ≥ 3 logMAR lines (0.3 logMAR) or ≥ 15 letters o When participants return for the Spectacle Baseline / Randomization Visit with their new spectacles, they will need to meet the same criteria as above using the ATS-HOTV or E-ETDRS protocol after wearing the new spectacles for at least 10 minutes (based upon the mean of a test and retest of VA in those new spectacles).
  • 6. Investigator is willing to prescribe spectacle wear followed sequentially by patching or simultaneous spectacles and patching treatment per protocol.
  • 7. Parent understands the protocol and is willing to accept randomization.
  • 8. Parent has phone (or access to phone) and is willing to be contacted by Jaeb Center staff or other study staff.
  • 9. Relocation outside of area of an active PEDIG site for this study within the next 56 weeks is not anticipated.
  • Exclusion Criteria:
  • 1. Myopia greater than -6.00 D spherical equivalent in either eye.
  • 2. Previous intraocular or refractive surgery.
  • 3. Planned strabismus surgery in the next 56 weeks.
  • 4. Any previous treatment for amblyopia (patching, atropine, Bangerter filter, vision therapy, or binocular treatment).
  • 5. Previous spectacle or contact lens wear for more than 24 hours.
  • 6. Parent and participant willing to forego option of contact lens wear for the duration of the study.
  • 7. Ocular co-morbidity that may reduce VA determined by an ocular examination performed within the past 7 months (Note: nystagmus per se does not exclude the participant if the above VA criteria are met).
  • 8. Severe developmental delay that would interfere with treatment or evaluation (in the opinion of the investigator). Participants with mild speech delay or reading and/or learning disabilities or attention deficit hyperactivity disorder (ADHD) are not excluded.
  • 9. Known allergy to adhesive patches.
  • 10. Known allergy to silicone.

About Jaeb Center For Health Research

The Jaeb Center for Health Research is a leading nonprofit organization dedicated to advancing medical research through innovative clinical trials and data analysis. With a strong emphasis on improving patient outcomes, the Center collaborates with healthcare professionals and institutions to conduct rigorous studies across various therapeutic areas, particularly in ophthalmology and diabetes. By leveraging cutting-edge methodologies and a commitment to ethical research practices, the Jaeb Center strives to enhance the understanding of disease mechanisms and develop effective treatment options, ultimately contributing to the improvement of public health.

Locations

Rochester, Minnesota, United States

Baltimore, Maryland, United States

Houston, Texas, United States

Birmingham, Alabama, United States

Palo Alto, California, United States

Boston, Massachusetts, United States

Jacksonville, Florida, United States

Sacramento, California, United States

Kansas City, Missouri, United States

Durham, North Carolina, United States

Rochester, Minnesota, United States

Chicago, Illinois, United States

Lubbock, Texas, United States

Tucson, Arizona, United States

Philadelphia, Pennsylvania, United States

Oklahoma City, Oklahoma, United States

Portland, Oregon, United States

Cincinnati, Ohio, United States

Baltimore, Maryland, United States

Akron, Ohio, United States

Laramie, Wyoming, United States

Bloomington, Indiana, United States

Columbus, Ohio, United States

Tucson, Arizona, United States

Loma Linda, California, United States

New York, New York, United States

Erie, Pennsylvania, United States

Memphis, Tennessee, United States

Birmingham, Alabama, United States

Omaha, Nebraska, United States

West Des Moines, Iowa, United States

Chapel Hill, North Carolina, United States

Spokane, Washington, United States

Salt Lake City, Utah, United States

New York, New York, United States

Seattle, Washington, United States

Fullerton, California, United States

Norfolk, Virginia, United States

San Antonio, Texas, United States

Lancaster, Pennsylvania, United States

Glendale, Arizona, United States

Pomona, California, United States

San Francisco, California, United States

Fort Lauderdale, Florida, United States

Boise, Idaho, United States

Downers Grove, Illinois, United States

Grand Rapids, Michigan, United States

Grand Rapids, Michigan, United States

Saint Louis, Missouri, United States

Philadelphia, Pennsylvania, United States

Chicago Ridge, Illinois, United States

Lisle, Illinois, United States

Saint Louis, Missouri, United States

Columbia, South Carolina, United States

Boston, Massachusetts, United States

Nashville, Tennessee, United States

San Antonio, Texas, United States

Indianapolis, Indiana, United States

Milford, Connecticut, United States

Sartell, Minnesota, United States

Buffalo, New York, United States

Albany, Oregon, United States

Fort Worth, Texas, United States

San Antonio, Texas, United States

Irvine, California, United States

Phoenix, Arizona, United States

Berkeley, California, United States

Grand Rapids, Michigan, United States

Los Angeles, California, United States

Tampa, Florida, United States

New York, New York, United States

Patients applied

0 patients applied

Trial Officials

Vivian Manh

Study Chair

Seattle Children's Hospital, University of Washington

Michael Gray

Study Chair

Children's Hospital Medical Center, Cincinnati

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials